Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Admission hyperglycemia is common in subjects with acute myocardial infarction (AMI). Reperfusion therapy with primary percutaneous coronary intervention (PPCI) represents the leading therapeutic choice, in particular in ST-segment elevation myocardial infarction (STEMI). Despite this, mortality, re-hospitalizations and complications remain a relevant problem. Adenosine, a purine nucleoside, may reduce no-reflow. Therefore, whe studied the effects of intravenous infusion of adenosine in addition to primary percutaneous coronary intervention (PPCI) in hyperglycemic patients with STEMI.
Methods: We evaluated 836 patients with STEMI and admission hyperglycemia (glycemia >140 mg/dL). At the end, 399 patients were entered into the database. Patients were grouped on the basis of whether they received adenosine or not.
Results: A total of 199 patients received intravenous adenosine infusion and PPCI and 200 patients did not. Kaplan-Meier analysis demonstrated significant differences in all death, cardiac death, re-hospitalization for heart failure and for acute coronary syndrome in the adenosine treated group.
Conclusions: The effects of intravenous infusion of adenosine and PPCI on clinical outcomes are significant but we need future larger studies with larger follow-up and statistical analysis to confirm our results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjms.2021.06.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Daylight Savings Time and Acute Myocardial Infarction.
JAMA Netw Open
September 2025
Division of Cardiology, Duke University Hospital, Durham, North Carolina.
Importance: Previous data suggest that the time changes associated with daylight savings time (DST) may be associated with an increased incidence of acute myocardial infarction (AMI).
Objective: To determine whether the incidence of patients presenting with AMI is greater during the weeks during or after DST and compare the in-hospital clinical events between the week before DST and after DST.
Design, Setting, And Participants: This cross-sectional study examined patients enrolled in the Chest Pain MI Registry from 2013 to 2022.
Outcomes after percutaneous coronary intervention or coronary artery bypass grafting in patient with left main coronary artery disease: the TOkai LEft main RevAscularizatioN sTrategy (TOLERANT) study.
Cardiovasc Interv Ther
September 2025
Division of Cardiovascular Medicine, Toyohashi Heart Center, Aichi, Japan.
The outcome of percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) is still controversial for patients with left main coronary artery (LMCA) disease. This multicenter cohort study aimed to evaluate the clinical outcomes of LMCA disease patients who underwent PCI or CABG. We reviewed 875 consecutive patients diagnosed with LMCA disease between January 2009 and December 2020 who underwent coronary revascularization by PCI (n = 404) or CABG (n = 471).
View Article and Find Full Text PDFEfficacy of sonothrombolysis as an adjunct to primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: a systematic review and meta-analysis.
J Thromb Thrombolysis
September 2025
Faculty of Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt.
In this review, we aimed to evaluate Sonothrombolysis when combined with primary percutaneous coronary intervention (pPCI) in STEMI patients with regard to improving cardiac function and clinical outcomes. This study primarily assesses short-term efficacy outcomes, while long-term impacts, such as mortality, were not evaluated. Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we searched four electronic databases (PubMed, Scopus, Cochrane Library, and Web of Science) to identify eligible studies reported up to November 2024.
View Article and Find Full Text PDFValidation of angiography-based FFR in non-culprit vessels of patients presenting with STEMI.
Clin Res Cardiol
September 2025
Department of (Interventional) Cardiology, Thoraxcenter, Erasmus University Medical Center, Room Rg-628, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands.
Background: Fractional flow reserve (FFR) for non-culprit lesions (NCLs) in patients with ST-elevation myocardial infarction (STEMI) can be influenced by temporary changes in microvascular resistance. Angiography-derived vessel fractional flow reserve (vFFR) has been tested as a less-invasive alternative.
Aims: The FAST STEMI II study aimed to assess the diagnostic performance of acute-setting vFFR vs.
Ranolazine-Induced Type 1 Brugada Pattern.
JACC Case Rep
September 2025
Cardiovascular Diseases Section, Interdisciplinary Department of Medicine (DIM), University of Bari "Aldo Moro," Bari, Italy.
Background: Brugada syndrome (BrS) is a rare inherited arrhythmia disease carrying a variable risk of sudden cardiac death. Diagnosis requires the type 1 Brugada electrocardiographic pattern, which can either be spontaneous or induced by sodium channel-blocking drugs. Ranolazine is an antianginal drug acting on the late sodium current with emerging antiarrhythmic properties; no information is available on the safety of ranolazine use in patients with BrS.
View Article and Find Full Text PDF